Clinical trials: Vaccine Response
IBD, Covid19
Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases
The 2019-coronavirus disease (COVID-19), caused by SARS-CoV-2, was identified as the source of pneumonia cases in Wuhan city in China. It rapidly spread worldwide and was declared by WHO as a pandemic.
- Trial name
- NCT05067959
- Testing
- Covid-19 vaccine
- Where
- Israel
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Rabin Medical Center
Pneumococcal Infections, HIV Infections
Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women
HIV-infected people and pregnant women are at risk of developing severe pneumococcal disease. The purpose of this study is to compare the safety and immune response to two pneumococcal vaccines in HIV-infected pregnant women.
- Trial name
- NCT01443117
- Testing
- PPV-23 Vaccine, PCV-13 Vaccine
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
TIV Infant/Toddler Response Evaluation (TITRE)- Follow-up & Focus on Influenza B
Each winter, viruses belonging to two kinds of influenza A ("A/H1N1" \& "A/H3N2") and two kinds of influenza B ("B/Yamagata" \& "B/Victoria") can cause illness.
- Trial name
- TITRE II (NCT01067404)
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 3 sites in Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- British Columbia Centre for Disease Control
Schistosomiasis, Anemia
Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal
SchistoVAN aims to study the role of schistosomiasis infection in the modulation of the immune response of children to childhood vaccine antigens, as well as the impact of this infection on their nutritional status and their…
- Conditions
- Schistosomiasis, Anemia, Underweight, Stunting
- Trial name
- SchistoVAN (NCT01553552)
- Where
- Senegal
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Biomedical Research Center EPLS
Presence of Materials From PCV-1
Assessment of the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants and Toddlers, Following Administration of IPV (Inactivated Poliovirus Vaccine)-Containing Vaccines
This study aims to analyse the serologic response to PCV-1 in the PEDIARIX® [GSK Biologicals' Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine] and…
- Trial name
- NCT01651247
- Testing
- Serum sample
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immune Responses, Antibiotic Treatment
The Effects of Antibiotic Exposure in Early Infancy on Vaccine Responses
This prospective cohort study will include 200 term children born in Landspitali University Hospital in Iceland. The cohort will be divided into four groups according to antibiotic exposure of which one is the control group.
- Trial name
- NCT06079606
- Testing
- Antibiotic treatment
- Where
- Iceland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Landspitali University Hospital
Meningococcal Infections
Regulation of Mucosal Immune Response to Systemic MenB Vaccine
Meningitis or septicaemia (blood poisoning) caused by group B meningococcal infection (MenB) is an important cause of death and disability in the UK. Prevention through vaccination therefore remains a key public health priority.
- Trial name
- NCT00774384
- Testing
- NZ MenB OMV vaccine (NZ98/254)
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Influenza
ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults
Influenza infection is related to significant morbidity and mortality in children. The trivalent inactive vaccine (TIV) has been documented to have poor immunogenicity in children and the live attenuated influenza vaccine (ATIV)…
- Trial name
- NCT02529904
- Testing
- MF59 - ATIV
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Bordetella Pertussis, Whooping Cough
Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
This study evaluates the safety and immunogenicity of the BPZE1 live, attenuated pertussis vaccine, intended to prevent nasopharyngeal colonization and pertussis disease, and compares BPZE1 vaccine vs Boostrix vaccine vs both…
- Trial name
- NCT05116241
- Testing
- BPZE1 pertussis vaccine and Boostrix
- Where
- 16 sites in Australia, Costa Rica and 1 more
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- ILiAD Biotechnologies
Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella)…
- Trial name
- NCT07406360
- Testing
- MMRVNS, MMRV
- Where
- 17 sites in United States
- Volunteers
- 1,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cholera
Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine
Cholera is a major health problem of many developing countries and marked increase in the prevalence has been seen on all continents in the last decade (WHO 1998).
- Trial name
- NCT00464867
- Testing
- Whole cell killed cholera vaccine & probiotic
- Where
- Bangladesh
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Chikungunya Virus Infection
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control.
- Trial name
- NCT06106581
- Testing
- VLA1553 full dose, VLA1553 half dose, Control
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
HIV Infections, Influenza
Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents.
- Trial name
- NCT00091702
- Testing
- Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV)
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Response to MMR Vaccine
Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children
This is a study planned to determine and compare immunogenicity and reactogenicity of MMR vaccine of SIIL delivered either with disposable-Syringe Jet Injector (DSJI) or disposable-syringe needle in total 340 Indian infants aged…
- Trial name
- NCT02253407
- Testing
- MMR vaccine
- Where
- 6 sites in India
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Celiac Disease
Response to Hepatitis B Vaccine in Celiac Disease Patients
Celiac disease and infection with hepatitis B virus (HBV) are very prevalent worldwide and carry a high morbidity rate. It has been recently shown that patients with celiac disease very often fail to develop immunity after…
- Trial name
- NCT00739128
- Testing
- hepatitis B vaccine (EngerixB)
- Where
- Israel
- Volunteers
- 210 people
- Sponsor
- Shaare Zedek Medical Center
Influenza
Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity
The purpose of this study is to compare the antibody response and reaction rates in children age 6-23 months when they are given either the currently recommended schedule of two 0.25ml doses of influenza vaccine one month apart…
- Trial name
- TITRE (NCT00710866)
- Testing
- Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)
- Where
- 5 sites in Canada
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- British Columbia Centre for Disease Control
Respiratory Syncytial Virus Infections
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children. This study will evaluate the safety and immune response to an RSV vaccine in healthy RSV-naïve children.
- Trial name
- NCT01968083
- Testing
- RSV cps2 Vaccine
- Where
- 5 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Virus Vaccine Adverse Reaction, Influenza Vaccine Allergy
Immune Response and Risk of Side Effects After Influenza Vaccination in Athletes
Seasonal influenza vaccination was used to assess whether induction of immunity as well as the rate of side effects is influenced by the timing of the last training session before vaccination.
- Trial name
- NCT03654937
- Testing
- Influenza Vaccination
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Universität des Saarlandes
Paramyxoviridae Infections, Virus Diseases
Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants
Human parainfluenza viruses (HPIVs) are a major health concern in infants and young children under 5 years of age, causing serious respiratory tract disease.
- Trial name
- NCT00308412
- Testing
- rHPIV3cp45
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hematopoietic Stem Cell Transplant, Hematologic Malignancy
Influenza Vaccine Post Allogeneic Transplant
Study Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine…
- Trial name
- NCT01215981
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota